tb-403
mAbexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2008 (NCT00702494)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Placenta growth factorINHIBITOR
PGF inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS46MVG4H2LF ↗
- ChEMBLCHEMBL2109545 ↗
Also known as
- tb-403
- tb-403
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02748135 | Phase 1/Phase 2 (Phase 2) | May 1, 2016 | BioInvent International AB, Neuroblastoma and Medulloblastoma Translational Research Consortium, Oncurious NV |
| NCT00702494 | Phase 1 | Jun 1, 2008 | BioInvent International AB, Oxurion NV., University of Copenhagen |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioInvent International AB | For profit | 2 | 1 | 2 | 2008 |
| Neuroblastoma and Medulloblastoma Translational Research Consortium | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Oncurious NV | For profit | 1 | 1 | 1 | 2016 |
| Oxurion NV. | For profit | 1 | 0 | 1 | 2008 |
| University of Copenhagen | Academic/Hospital | 1 | 0 | 1 | 2008 |
5 organizations
Page 1 / 1